Scalper1 News
Specialty drugmaker Horizon Pharma (HZNP) agreed to buy privately held Crealta Holdings for $510 million in cash Friday, bringing it an orphan-disease drug with a troubled history. Last year, Crealta acquired Savient, maker of Krystexxa, a treatment for refractory gout. Krystexxa was launched in 2010 but never reached its full potential, according to Cowen analyst Eric Schmidt. “Savient admitted that Krystexxa’s launch was under-resourced, owing Scalper1 News
Scalper1 News